Sales turnover dented Biodesix's latest quarter, and management is already responding.
BDSX Biodesix, Inc.
XNAS
13.14
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BDSX
$13.14
—
What changed
Recent filings, trades and moves- Nov 5 8-K: Director or officer change
- Nov 5 8-K: Earnings results
Key stats
$13.14
- 52-Week Range
- $5.26 – $31.97
- YTD
- +103.41%
- Straddle Price
- $1.58
- P/C Vol Ratio (Apr 17 expiry)
- 7.36
- Market Cap
- $0.1B
- Open
- $8.32
- Day Range
- $7.70 – $10.94
- Volume
- 908,459
- Prev Close
- $8.53
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.79 |
| Cost of Equity (CAPM) | 8.85% (VRP-adj) |
| WACC | 7.78% |
| Volatility Risk Premium | -251.6pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -303.6% |
| Book / Price | 9.5% |
| Gross Margin (TTM) | 82.4% |
| FCF Margin (TTM) | -19.2% |
| Debt / Equity | 5.43 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $25.53 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $22.31 |
| Bollinger Width / SMA20 | 62.9% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
Peers used for multiples: CDNA, GH, GMAB, MRNA, QGEN, RVMD, TECH, VRTX
Blended Fair Value
$72.63
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.6× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 32.5× · 3 peers |
| Peer P/B | $6.98 | 50% | median 8.6× · 5 peers |
| Peer P/S | $138.28 | 50% | median 14.0× · 6 peers |
| Market Anchor (SMA50) | $25.53 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SERVICES-MEDICAL LABORATORIES (8071) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 334
- List Date
- 2020-10-28
- CIK
- 0001439725
- Last Earnings
- Aug 5
- Headquarters
- Louisville, CO
- Homepage
- https://www.biodesix.com
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 22.12% | -31.33% | 17.07% | 12.36% | -30.41% | 57.43% | 7.87% |
| Feb | -18.70% | -40.35% | -13.08% | -27.01% | -21.49% | 48.98% | -11.94% |
| Mar | 6.67% | -28.09% | -7.00% | -9.49% | -12.31% | -7.94% | -9.69% |
| Apr | -19.33% | -16.15% | -6.99% | -15.65% | -11.83% | -25.61% | -15.93% |
| May | -8.49% | -23.71% | -15.66% | 14.40% | -42.59% | 47.29% | -4.79% |
| Jun | -11.52% | 18.84% | -11.51% | 14.18% | -8.91% | 47.68% | 8.13% |
| Jul | -26.53% | 25.00% | -1.65% | 7.52% | 22.54% | -13.04% | 2.31% |
| Aug | -7.39% | -16.00% | 9.79% | 20.25% | 17.46% | 19.59% | 7.28% |
| Sep | -14.37% | -30.60% | 7.84% | -3.78% | -12.94% | 18.99% | -5.81% |
| Oct | -13.03% | -19.20% | -16.96% | -3.95% | -10.95% | -14.91% | -13.17% |
| Nov | -12.45% | 92.31% | 7.19% | 10.77% | 30.60% | -52.53%* | 12.65% |
| Dec | -16.43% | 53.33% | 23.49% | 12.50% | -12.71% | -- | 12.04% |
| Total | -74.35% | -61.12% | -15.92% | 21.78% | -71.90% | 74.63% | -21.15% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $21.54
SMA 50: $25.20
SMA 200: $18.89
Current: $10.34
EMA 12: $18.65
EMA 26: $21.65
MACD: -2.9987 | Signal: -1.2530
BEARISH
ADX (14): 31.09
TREND
+DI: 7.50
−DI: 45.09
Momentum Oscillators
RSI (14): 24.23
OVERSOLD
Stoch %K: 10.35
Stoch %D: 14.62
Williams %R: -84.79
Volume & Volatility
BB Upper: $30.09
BB Lower: $12.98
OVERSOLD
OBV: 94,053,353
Vol SMA 20: 203,713
Vol ROC: 1389.15%
ATR: $2.70
True Range: $3.24
HV 20: 316.2%
HV 30: 259.5%
HV 60: 194.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before BDSX’s Nov 5 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary Overall assessment: BULLISH (confidence level: 8/10) Key drivers: Technical momentum, positive news sentiment Primary risks: Volatility, potential breakouts/breakdowns Investment thesis: Biodesix's recent financial results and participation in investor conferences have generated positive market perception, supporting a bullish technical picture. Recent news sentiment impact: Positive news headlines have contributed to the stock's upward trend.
Technical Analysis
- Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Bullish; Long-term (3-12 months): Neutral
- Support/Resistance Levels: Upper Bollinger Band: $25.65, Middle Line: $20.14, Lower Bollinger Band: $14.62
- Momentum Signals:
- RSI interpretation: 57.21 (neutral)
- MACD signal: Bullish (1.47 / -0.18 / 1.64)
- Bollinger Bands position: Neutral (price within bands)
News & Sentiment Analysis
- Recent Headlines Summary: Biodesix's participation in investor conferences and preliminary financial results have generated positive news sentiment.
- Sentiment Assessment: Positive news sentiment dominates, with 5 out of 6 recent headlines having a positive tone.
- Catalyst Identification: Earnings report on May 4, 2026; upcoming investor conferences
- Market Narrative: Technical momentum and positive news sentiment have created a bullish narrative.
Risk & Volatility Assessment
- Beta Interpretation: Beta: 0.81 (vs SPY) - Moderate volatility - stock generally follows market
- Volatility Regime: Current vs historical volatility levels: Low (1.15)
- Options Market Signals:
- IV Rank: 0.0% (Low)
- Current IV: 0.0%
- Expected Move: $1.58 (0 DTE), 7-DTE: $1.58
- Volume Flow: 14 calls vs 103 puts
- Open Interest: 1,165 calls vs 114 puts
- Downside Protection: Support levels: Lower Bollinger Band ($14.62), SMA 50 ($17.00)
Market Context & Positioning
- Sector Performance: Biodesix's industry (Healthcare) has shown moderate strength.
- Institutional Activity: No significant institutional activity detected.
- Correlation Analysis: Correlation: 0.09 - stock generally follows market
- Relative Valuation: Position within trading range: Neutral
Key Levels & Action Items
- Critical Price Levels: Upper Bollinger Band ($25.65), Middle Line ($20.14)
- Breakout/Breakdown Levels: SMA 200 ($11.86) - potential support/resistance
- Time-Sensitive Catalysts: Earnings report on May 4, 2026; upcoming investor conferences
- Risk Management: Stop-loss levels: Lower Bollinger Band ($14.62), position sizing considerations: 2-3% of portfolio
Conclusion
Biodesix's recent financial results and positive news sentiment have generated a bullish technical picture. The stock is positioned within a trading range, with moderate volatility and institutional activity absent. Key levels to monitor include the upper Bollinger Band ($25.65) and SMA 200 ($11.86). Risk management considerations suggest a stop-loss level at the Lower Bollinger Band ($14.62) and position sizing of 2-3% of portfolio.
Generated
News
All BDSX news →
Earnings History
10 of 11 under expected move
Avg Expected Move
267.63%
Avg Actual Move
11.75%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-05-11 | Pre-Market | 10.36% | 15.41% | 1.49x | Exceeded |
| 2023-05-11 | Pre-Market | 59.47% | 4.27% | 0.07x | Within |
| 2023-08-07 | Pre-Market | 58.86% | 2.53% | 0.04x | Within |
| 2024-08-07 | Pre-Market | 89.62% | 0.00% | 0.00x | Within |
| 2024-11-01 | Pre-Market | 110.29% | 23.53% | 0.21x | Within |
| 2025-03-03 | Pre-Market | 175.58% | 10.09% | 0.06x | Within |
| 2025-05-13 | Pre-Market | 1979.76% | 0.08% | 0.00x | Within |
| 2025-08-07 | After-Close | 249.13% | 10.40% | 0.04x | Within |
| 2025-11-03 | Pre-Market | 109.08% | 7.17% | 0.07x | Within |
| 2026-01-12 | Pre-Market | 90.66% | 47.99% | 0.53x | Within |
| 2026-02-26 | After-Close | 11.11% | 7.81% | 0.70x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BDSX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.58
7-DTE Move: $1.58
Days to Exp: — (2026-04-17)
Options Flow · Apr 17 expiry
Call Volume: 14
Put Volume: 103
P/C Volume: 7.357
BEARISH
Call OI: 1,165
Put OI: 114
P/C OI: 0.098
Total OI: 1,279
ATM Options Pricing
ATM Call: $0.23
ATM Put: $1.35
Call %: 1.7%
Put %: 10.3%
Chain Summary
Chain Volume: 117
Chain OI: 1,279
Last Updated: 4/17/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Apr 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Apr 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.58Apr 17
Beta Analysis
Risk Metrics
Beta: 1.3112
Alpha: 93.27%
Correlation: 0.1480
R-Squared: 2.2%
Stock Volatility: 121.8%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BDSX
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $646K | #2502 of 3138 | +139.8% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $325K | #3324 of 3716 | -40.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BDSX Institutional Ownership (13F)
Filings for 2026-06-30 · 13 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 9,670,750 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BDSX Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | John Patience | Director | Exer (M) | +1,360 | — | EDGAR | |
| 2026-08-13 | Jack W Schuler | 10%+ Owner | Buy (P) | +15,000 | $24.47 | $367.0K | EDGAR |
| 2026-08-12 | Jack W Schuler | 10%+ Owner | Buy (P) | +27,600 | $24.13 | $665.9K | EDGAR |
| 2026-07-02 | John Patience | Director | Exer (M) | +1,361 | — | EDGAR | |
| 2026-04-02 | John Patience | Director | Exer (M) | +1,361 | — | EDGAR | |
| 2026-02-23 | Kieran O'Kane | Chief Commercial Officer | Mixed Exer +1,469 · Sell −535 |
+934 | $12.78 | -$6.8K | EDGAR |
| 2026-02-23 | Scott Hutton | President & CEO | Mixed Sell −1,490 · Exer +4,844 |
+3,354 | $12.78 | -$19.0K | EDGAR |
| 2026-02-23 | Robin Harper Cowie | CFO, Sec'y & Treasurer | Mixed Exer +1,469 · Sell −535 |
+934 | $12.78 | -$6.8K | EDGAR |
| 2026-02-23 | Chris Vazquez | Chief Accounting Officer | Mixed Exer +563 · Sell −211 |
+352 | $12.78 | -$2.7K | EDGAR |
| 2026-02-23 | Gary Anthony Pestano | Chief Development Officer | Mixed Exer +1,528 · Sell −556 |
+972 | $12.78 | -$7.1K | EDGAR |
| 2026-02-11 | Kieran O'Kane | Chief Commercial Officer | Mixed Sell −584 · Exer +1,600 |
+1,016 | $10.08 | -$5.9K | EDGAR |
| 2026-02-11 | Scott Hutton | President & CEO | Mixed Exer +9,998 · Sell −3,559 |
+6,439 | $10.08 | -$35.9K | EDGAR |
| 2026-02-11 | Gary Anthony Pestano | Chief Development Officer | Mixed Sell −540 · Exer +1,481 |
+941 | $10.08 | -$5.4K | EDGAR |
| 2026-02-11 | Robin Harper Cowie | CFO, Sec'y & Treasurer | Mixed Sell −941 · Exer +2,584 |
+1,643 | $10.08 | -$9.5K | EDGAR |
| 2026-02-11 | Chris Vazquez | Chief Accounting Officer | Mixed Sell −101 · Exer +263 |
+162 | $10.08 | -$1.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BDSX Insider Holdings
13 insiders · @ $10.34
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jack W Schuler | Director | 555,810 | $5.75M | $51.95M | 47 | 2026-08-13 |
| 2 | Lawrence T. Kennedy Jr | Director | 138,769 | $1.43M | $12.64M | 11 | 2026-01-06 |
| 3 | Matthew Strobeck | Director | 133,096 | $1.38M | $6.89M | 18 | 2026-01-06 |
| 4 | Scott Hutton | President & CEO | 50,257 | $519.7K | -$305.7K | 31 | 2026-02-23 |
| 5 | John Patience | Director | 29,392 | $303.9K | $4.04M | 27 | 2026-10-02 |
| 6 | Charles M Watts | Director | 21,085 | $218.0K | $111.1K | 15 | 2025-04-02 |
| 7 | Hany Massarany | Director | 18,175 | $187.9K | $315.9K | 15 | 2026-01-06 |
| 8 | Jon Faiz Kayyem | Director | 17,877 | $184.8K | $200.0K | 13 | 2026-01-06 |
| 9 | Robin Harper Cowie | CFO, Sec'y & Treasurer | 16,231 | $167.8K | -$94.3K | 33 | 2026-02-23 |
| 10 | Gary Anthony Pestano | Chief Development Officer | 10,359 | $107.1K | -$69.1K | 30 | 2026-02-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BDSX Board & Officers
As of SEC filings through Oct 2, 2026Directors 7
- Hany Massarany · since Oct 27, 2020
- Jean M. Franchi · since Oct 27, 2020
- John Patience · since Oct 27, 2020
- Matthew Strobeck · since Oct 27, 2020
- Scott Hutton · since Oct 27, 2020
- Jon Faiz Kayyem · since Dec 6, 2021
- Lawrence T. Kennedy Jr · listed since Jan 2023
Officers 5
- Scott Hutton · President & CEO · since Oct 27, 2020
- Robin Harper Cowie · CFO, Sec'y & Treasurer · since Oct 27, 2020
- Gary Anthony Pestano · Chief Development Officer · since Oct 27, 2020
- Kieran O'Kane · Chief Commercial Officer · since Oct 27, 2020
- Chris Vazquez · Chief Accounting Officer · since Jul 3, 2023
10% owners 2
- Jack W Schuler · since Oct 27, 2020
- Lawrence T. Kennedy Jr · since Apr 7, 2022
Changes in the last 10 years (30)
| Apr 15, 2025 | The company announced the departure of Jack W Schuler from the board in an SEC filing |
| Apr 15, 2025 | The company announced the departure of Charles M Watts from the board in an SEC filing |
| Jan 3, 2024 | John Patience no longer listed as a 10% owner in SEC filings |
| Jul 3, 2023 | Chris Vazquez became Chief Accounting Officer |
| May 31, 2023 | The company announced the departure of Ryan H Siurek as Chief Accounting Officer in an SEC filing |
| Jan 5, 2023 | Lawrence T. Kennedy Jr first listed as a director in an SEC filing |
| Jan 4, 2023 | John Patience first listed as a 10% owner in an SEC filing |
| Apr 7, 2022 | Lawrence T. Kennedy Jr became a 10% owner |
| Feb 10, 2022 | Robert William Georgantas III no longer listed as a director in SEC filings |
| Feb 10, 2022 | Robert William Georgantas III listed as Chief Scientific Officer (previously SVP, Rsrch & Trans'l Science) in SEC filings |
| Dec 6, 2021 | Jon Faiz Kayyem became a director |
| Dec 31, 2020 | Ryan H Siurek became Chief Accounting Officer |
| Nov 3, 2020 | Robert William Georgantas III first listed as a director in an SEC filing |
| Nov 3, 2020 | John Patience no longer listed as a 10% owner in SEC filings |
| Nov 3, 2020 | John Patience no longer listed as Chairman in SEC filings |
| Oct 27, 2020 | Scott Hutton became a director |
| Oct 27, 2020 | Scott Hutton became President & CEO |
| Oct 27, 2020 | Robin Harper Cowie became CFO, Sec'y & Treasurer |
| Oct 27, 2020 | Robert William Georgantas III became SVP, Rsrch & Trans'l Science |
| Oct 27, 2020 | Matthew Strobeck became a director |
| Oct 27, 2020 | Kieran O'Kane became Chief Commercial Officer |
| Oct 27, 2020 | John Patience became a director |
| Oct 27, 2020 | John Patience became a 10% owner |
| Oct 27, 2020 | John Patience became Chairman |
| Oct 27, 2020 | Jean M. Franchi became a director |
| Oct 27, 2020 | Jack W Schuler became a director |
| Oct 27, 2020 | Jack W Schuler became a 10% owner |
| Oct 27, 2020 | Hany Massarany became a director |
| Oct 27, 2020 | Gary Anthony Pestano became Chief Development Officer |
| Oct 27, 2020 | Charles M Watts became a director |
Not reported recently (1)
- Robert William Georgantas III · Last reported as Chief Scientific Officer in an SEC filing dated Nov 21, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BDSX Proposed Insider Sales (Form 144)
Latest: 2026-02-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | Hutton Scott | Officer, Director | 1,490 | $19.0K | 2026-02-23 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-02-11 | Hutton Scott | Officer, Director | 83,660 | $79.5K | 2025-02-11 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-02-11 | Cowie Robin Harper | Officer | 24,664 | $23.4K | 2025-02-11 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-02-11 | Pestano Gary Anthony | Officer | 16,748 | $15.9K | 2025-02-11 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-02-11 | O'Kane Kieran | Officer | 17,527 | $16.7K | 2025-02-11 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2024-05-09 | Pestano Gary Anthony | Officer | 434 | $673 | 2024-05-09 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2024-05-09 | O'Kane Kieran | Officer | 468 | $725 | 2024-05-09 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2024-05-09 | Hutton Scott | Officer, Director | 3,764 | $5.8K | 2024-05-09 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2024-05-09 | Cowie Robin Harper | Officer | 980 | $1.5K | 2024-05-09 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2024-02-09 | Pestano Gary Anthony | Officer | 10,884 | $21.7K | 2024-02-09 | Morgan Stanley Smith Barney LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
4 ETFs hold BDSX
4 shown · $8.38M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $6.1M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.1M | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $145,019 | $1.2B | 2026-11-06 |
| 4 | GNMX Corgi Genomics & Precision Medicine ETF | Corgi | 0.20% | $2,508 | $1.3M | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.76
TTM Revenue
$105.21M
TTM Net Income
$-27.08M
TTM Op. Cash Flow
$-18.16M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $24.04M | $-8.03M | $-0.75 | $-7.20M |
| Q2 '26 | 2026-06-30 | $26.86M | $-7.27M | $-0.71 | $-1.56M |
| Q1 '26 | 2026-03-31 | $25.55M | $-7.79M | $-0.81 | $-10.17M |
| Q4 '25 | 2025-12-31 | $28.75M | $-3.98M | $-0.43 | $778.00K |
| Q3 '25 | 2025-09-30 | $21.77M | $-8.72M | $-1.16 | $-8.88M |
| Q2 '25 | 2025-06-30 | $20.02M | $-11.47M | $-1.56 | $-6.57M |
| Q1 '25 | 2025-03-31 | $17.96M | $-11.10M | $-1.52 | $-8.60M |
| Q4 '24 | 2024-12-31 | $20.43M | $-8.25M | $-1.03 | $-4.10M |
| Q3 '24 | 2024-09-30 | $18.15M | $-10.26M | $-1.40 | $-10.67M |
| Q2 '24 | 2024-06-30 | $17.93M | $-10.81M | $-1.60 | $-18.57M |
| Q1 '24 | 2024-03-31 | $14.82M | $-13.61M | $-2.80 | $-15.31M |
| Q4 '23 | 2023-12-31 | $14.67M | $-9.14M | $-1.80 | $-12.28M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
9.90
P/S
0.88
EV/EBITDA
—
EV/Sales
1.04
ROE
-303.6%
ROA
-29.1%
Div Yield
0.00%
FCF Yield
-21.92%
Debt/Equity
5.12
Current Ratio
—
Market Cap
$90.48M
as of 2026-11-09
BDSX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.8% | 64 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +771.7% | 53 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +153.3% | 60 |
| GMAB Genmab A/S ADS | $33.0B | — | — | +75.4% | 12 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +56.1% | 23 |
| TECH Bio-Techne Corp. | $11.4B | 63.3 | −0.4% | +22.1% | 36 |
| QGEN QIAGEN N.V. | $10.4B | — | — | +11.9% | 6 |
| CDNA CareDx, Inc. | $4.1B | 35.3 | +38.9% | +341.1% | 37 |
| BDSX Biodesix, Inc. Common Stock | $95M | — | +31.2% | +60.1% | — |
| Peer median | $26.7B | 35.4 | +10.5% | +65.7% | 37 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
209.50K
SI % of Float
5.12%
Days to Cover
2.35
Short Vol Ratio
55.5%
Free Float
4.09M
Float %
38.8%
Short interest 2026-10-15 • Short volume 2026-11-09 • Float 2026-11-02